Medication info
Sitagliptin and Metformin Prolonged-Release Tablets 50/500 mg

Sitagliptin and Metformin Prolonged-Release Tablets 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Shinpoong Pharmaceutical Co., Ltd.
Appearance
Pale blue, double convex, oval-shaped prolonged-release film-coated tablets
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300590 · Approved 2023.02.17 · Insurance code 648508160

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antihyperglycemic therapy, the dosage of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medication must be swallowed whole and not split, crushed, ground, or chewed. Cases have been reported in which the medication was incompletely dissolved and excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients. If a patient repeatedly reports finding this medication in the stool, the healthcare professional should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this medication 100/1000 mg extended-release tablets once daily. Patients taking this medication 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no prior experience of diabetes medication and inadequate blood glucose control with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Should Not Receive This Medication). 2. Patients receiving metformin treatment: For patients who cannot achieve adequate blood glucose control with metformin monotherapy, the recommended initial total daily dose of this medication is sitagliptin 100 mg and the patient's current metformin dose. Patients switching from concomitant sitagliptin and metformin therapy to this medication may start at their current doses of sitagliptin and metformin. Patients receiving immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medication 50/1000 mg extended-release tablets once daily. 3. Patients unable to achieve adequate blood glucose control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medication is sitagliptin 100 mg, and the initial metformin dose should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medication. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medication, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment Because this medication contains metformin, it should not be administered to patients with hepatic impairment (see Precautions for Use, 2. Patients Who Should Not Receive This Medication).

Ingredients

Manufacturer
Shinpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used in conjunction with dietary and exercise therapy to help patients with type 2 diabetes control their blood sugar levels. The components sitagliptin and metformin work together to effectively improve blood sugar levels. This helps stabilize the condition of patients who have difficulty controlling their blood sugar levels, thereby supporting healthy blood sugar management.

How to take

Adult dose

In antihyperglycemic therapy, the dosage of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medication must be swallowed whole and not split, crushed, ground, or chewed. Cases have been reported in which the medication was incompletely dissolved and excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients. If a patient repeatedly reports finding this medication in the stool, the healthcare professional should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this medication 100/1000 mg extended-release tablets once daily. Patients taking this medication 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no prior experience of diabetes medication and inadequate blood glucose control with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Should Not Receive This Medication). 2. Patients receiving metformin treatment: For patients who cannot achieve adequate blood glucose control with metformin monotherapy, the recommended initial total daily dose of this medication is sitagliptin 100 mg and the patient's current metformin dose. Patients switching from concomitant sitagliptin and metformin therapy to this medication may start at their current doses of sitagliptin and metformin. Patients receiving immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medication 50/1000 mg extended-release tablets once daily. 3. Patients unable to achieve adequate blood glucose control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medication is sitagliptin 100 mg, and the initial metformin dose should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medication. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medication, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment Because this medication contains metformin, it should not be administered to patients with hepatic impairment (see Precautions for Use, 2. Patients Who Should Not Receive This Medication).

Precautions

This medication contains sitagliptin and metformin. First, sitagliptin can cause rare but serious allergic reactions; therefore, if symptoms such as rash, difficulty breathing, or swelling of the face or neck occur, stop taking the medication immediately and consult a doctor. Also, acute pancreatitis, which is inflammation of the pancreas, may occur, so if symptoms such as abdominal pain, vomiting, or fever arise, inform medical personnel immediately. Metformin can lead to a rare but potentially fatal metabolic disorder known as lactic acidosis; therefore, it should not be administered to patients with severe dehydration, sudden renal function decline, severe infections, or heart disease. Additionally, excessive alcohol intake can increase the risk of lactic acidosis, so drinking should be avoided. This medication should not be administered to patients with moderate to severe renal impairment, acute heart failure, acute myocardial infarction, severe infections, or to women who are pregnant or breastfeeding. Before and during administration, regular kidney function and blood tests should be conducted to detect any abnormal signs early, and periodic checks of vitamin B12 levels are recommended. During treatment with this medication, blood sugar levels may drop due to irregular meals, intense exercise, or interactions with other medications, so caution should be exercised, and appropriate action should be taken immediately if symptoms of hypoglycemia (such as dizziness, cold sweat, or trembling) occur. When undergoing surgery or tests requiring contrast agents, take a break from this medication and restart only after confirming normal kidney function. Finally, safety and efficacy have not been established for patients under the age of 18, and elderly patients may have decreased kidney function, necessitating dose adjustments and careful monitoring.

Side effects

  • Severe allergic reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
Show 19 more
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • arthralgia with severe and disability
  • pemphigus vulgaris-like lesions
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • rash
  • urticaria
  • cutaneous vasculitis
  • acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it is best to avoid extremely hot or cold environments and to store it at room temperature, between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Pale blue, double convex, oval-shaped prolonged-release film-coated tablets

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.